Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.

CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.

IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.

Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.

China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.

Ruxolitinib helps regrow hair in alopecia areata by blocking inflammation, reducing stress, and controlling cell death.

Tofacitinib helped a man with alopecia totalis regrow all his hair.

New treatments for lupus show promise, but more research is needed, especially for children.

Combining delgocitinib ointment with excimer laser can effectively treat severe alopecia areata.

Baricitinib treatment can help regrow scalp hair and eyebrows or eyelashes in people with severe alopecia areata.

Erlotinib can cause scalp pustules and hair loss, needing early treatment with antibiotics and steroids.

Erlotinib can cause hair loss as a side effect.

Thymosin beta 4 protects cells from damage by blocking a harmful microRNA and boosting a protective gene.

Two new gene mutations cause a rare hair disorder.

Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.

Baricitinib 4 mg is effective and safe for treating severe alopecia areata.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

A reliable method was developed to measure Minoxidil and Tofacitinib in gel for hair loss treatment.

RTA 408 cream protects mice from radiation skin damage.

Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.

Erenumab significantly reduced migraine days or severity in most patients after 3 months.

Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.

Tofacitinib helped most teenagers in the study regrow hair with mild side effects.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.